Kornimate/medical-research-clean huggingface dataset:
the effect of different treatment modalities of class ii malocclusion on upper third molars.

Conditions: Third Molar Impaction

Summary: what is the effect of the different treatment modalities (distalization versus upper premolar extraction) of class ii malocclusion on the position, inclination and incidence of impaction of the upper third molars?

what is the effect of the different treatment modalities (distalization versus upper premolar extraction) of class ii malocclusion on the position, inclination and incidence of impaction of the upper third molars? pico p: adolescent patients with class ii malocclusion having bilateral developing upper third molars. i: bilateral upper first premolar extraction orthodontic treatment with moderate anchorage. c: distalization orthodontic treatment. o: primary: angulation of the maxillary third molars.

Eligibility criteria:
inclusion criteria: * adolescent males and females (16 -18 years) with bilaterally developing maxillary third molars. not more than two thirds of the root development of the third molars had taken place. * class ii malocclusion cases that were treated by 1) maxillary premolar extraction with a moderate anchorage requirement and achieved full unit class ii molar relationship or 2) distalization treatment plan and class i molar relationship was achieved. * patients with high-quality pre- and post-treatment radiographs. * normal or increased vertical dimension. exclusion criteria: * maxillary premolar extraction cases requiring maximum anchorage preparation. * low vertical dimension. * patients without dentofacial deformities, severe facial asymmetries, microdontia or hypodontia.

Keywords: distalization premolar extraction upper third molar impaction of third molar
ft516 in combination with monoclonal antibodies in advanced solid tumors

Conditions: Solid Tumor, Adult

Summary: this is a phase 1 dose-finding study of ft-516 in combination with monoclonal antibodies in participants with advanced solid tumors. the study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.


Eligibility criteria:
inclusion criteria: * locally advanced or metastatic solid tumor malignancies that have relapsed or progressed after at least one line of therapy and where the following anti-pd-l1 are approved: avelumab, atezolizumab or durvalumab * capable of giving signed informed consent * aged ≥ 18 years old * willingness to comply with study procedures and duration * measurable disease per irecist * contraceptive use for women and men as defined in the protocol exclusion criteria: * pregnant or breast-feeding women * ecog performance status ≥ 2 * evidence of insufficient organ function * clinically significant cardiovascular disease * receipt of therapy within 2 weeks prior to day 1 or five half-lives, whichever is shorter or any investigational therapy within 28 days prior to day 1 * known active central nervous system (cns) involvement by malignancy * non-malignant cns disease such as stroke, epilepsy, cns vasculitis or neurodegenerative disease or receipt of medications for these conditions * currently receiving or likely to require immunosuppressive therapy * known active infections with hepatitis b, hepatitis c or hiv * live vaccine within 6 weeks prior to start of lympho-conditioning * known allergy to albumin (human) or dmso

Keywords: pd-l1 cellular therapy nk cells urothelial cancer renal cell carcinoma merkel cell carcinoma non-small cell lung cancer nsclc triple negative breast cancer immune checkpoint inhibitor
neurophysiological intraoperative or epilepsy monitoring

Conditions: Patients Operated on at the Neurosurgery Department

Summary: the investigators record the outcome of patients whose surgery involved intraoperative neurophysiological monitoring * trial with surgical intervention


Eligibility criteria:
inclusion criteria: patients whose surgery involved intraoperative neurophysiological monitoring
supporting episodic memory with transcranial direct current stimulation in healthy controls and dementia patients

Conditions: Healthy; Mild Cognitive Impairment; Alzheimer Disease

Summary: previous studies showed that anodal tdcs applied over the dorsolateral prefrontal cortex (dlpfc) improved episodic memory performance, indicating a possible use as an intervention for patients suffering from memory impairments. at the same time, only scant evidence (provided by functional magnetic resonance imaging (fmri) and magnetic resonance spectroscopy (mrs)) exists regarding the underlying mechanisms, thus hindering a more targeted application. the present study aims at establishing a connection between the stimulation-induced change in episodic memory performance on the behavioural level and neurophysiological parameters. tdcs effects and the underlying mechanisms will be compared between different study conditions, receiving either real anodal tdcs or sham stimulation over the left dorsolateral prefrontal cortex during an episodic memory task.


Eligibility criteria:
inclusion criteria: * written informed consent * right-handedness * non-smokers * native german speakers or comparable level of fluency * normal or corrected-to-normal vision exclusion criteria: * neurological or psychiatric condition (other than diagnosed cognitive impairment) * past head injuries * magnetizable implants * history of seizures * current or life-time alcohol or drug abuse * pregnancy * skin diseases
effect of intravenous immunglobulin (ivig) after myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the instigators hypothesize that ivig, given in the acute phase following mi in patients at risk for developing hf, will improve cardiac performance, and by attenuating cardiac remodeling in this phase, such therapy will prevent the development of chronic hf resulting in long term beneficial effect also after the therapy has been stopped.

this double-blind placebo-controlled study represents a new approach to cardiovascular disease. the project deals with unresolved issues in the intersection between cardiology, immunology and molecular biology. ivig/placebo will be given as an induction therapy for 5 days and thereafter as monthly infusions for 5 months. change in left ventricular remodeling will be assessed at baseline, and 6 and 12 months with mri and echocardiography. the objectives are: 1. the primary objective of this study is to evaluate the effect on ivig on lv remodeling and function: lv remodeling will be evaluated with magnetic resonance imaging (mri) which offers an unsurpassed precision in the measurements of heart volumes and function. end points will be lv-end systolic and diastolic volume (lvesv, lvedv), regional wall motion score index (wmsi), and lv-ejection fraction (lv-ef). 2. the secondary objective of this study is to evaluate the effect on ivig on the myocardial marker b-type natriuretic peptide (bnp). bnp is a sensitive marker of the degree of hf besides being a prognostic indicator 18-20. 3. the tertiary objective of this study is to evaluate the effect on ivig on: a. quality of life. b. effect on new york heart association (nyha) functional class. c. effect on immunological variables. i. inflammatory cytokines such as tnf-alpha, il-6, il-18. ii. anti-inflammatory cytokines such as il-10 and transforming growth factor beta iii. chemokines such as monocyte chemoattractant protein 1, il-8 and ccl21. iv. regulators of hypertrophy such as matrix metalloproteinases, their endogenous inhibitors (i.e., timps) and procollagen iii n-terminal. d. effect on neurohormones. e. withdrawals. f. side effects.

Eligibility criteria:
inclusion criteria: * age of 18-80 years * have a recent mi (\<5days) * have asat \>100 u/l or ckmb \> 50 u/l. * have lvef \<40%. * are on optimal medical treatment and considered unsuitable for surgical intervention. exclusion criteria: * evidence of unstable disease, concomitant ischemia or unstable angina during the hospitalization. * significant concomitant disease such as infections, pulmonary disease or connective tissue disease. * participating in other studies. * inability to participate. * diseases that require surgery. * planned revascularisation. * known hypersensitivity to ivig.

Keywords: heart failure myocardial infarction patients with acute myocardial infarction
ms fatigue and tdcs on fatigue in multiple sclerosis

Conditions: Fatigue in Multiple Sclerosis

Summary: the available therapeutic strategies for multiple sclerosis (ms)-related symptoms are usually faced with limited efficacy and numerous side effects. patients with ms frequently suffer from fatigue, affective symptoms, and cognitive deficits.

for these reasons, non-invasive brain stimulation (nibs) techniques, namely transcranial direct current stimulation (tdcs) might be of help in this context. tdcs is a new nibs technique with a good safety profile, easy implementation, good patients' tolerance and little or no adverse effects. tdcs uses low levels of constant current delivered to specific brain area via sponge electrodes placed on the scalp. tdcs modifies the polarization of the exposed neuronal circuits. indeed, it modulates the spontaneous neuronal excitability and activity by a tonic depolarization or hyperpolarization of resting membrane potential. therefore, applying a home-based intervention is of interest in a population suffering from high levels of physical disability prohibiting them from frequently coming to seek care at the hospital

Eligibility criteria:
inclusion criteria: * definite ms diagnosis according to the 2017 mcdonald criteria * fatigue since more than 6 months as assessed by fatigue severity scale (fss\>5) * age between 18 and 75 years. * stable pharmacological and physical treatment since at least one month * affiliation to the social security regimen * signature of the informed consent * ability of the patient to understand the instructions for use of the pacemaker to ensure safe use exclusion criteria: * relapses within the last two months * active medical device implanted * intracranial metal implants * craniotomy, cranial trepanation, aneurysm * uncontrolled epilepsy * non-weaned alcoholism, sleep debt * expanded disability status scale ≥ 6.5 * severe depression based on beck depression inventory (bdi\>19) * daytime sleepiness based on epworth sleepiness scale (ess\> 11) * other neurologic and psychiatric diseases * known pregnancy by the investigator or breastfeeding * physical or mental incapacity to give informed consent * participation in another study (exclusion period following a previous study should be ≥ 6 months) * patients on ame * patients under legal protection * prisoners

Keywords: fatigue multiple sclerosis anodal tdcs prefrontal cortex
the experience of affective touch in obesity

Conditions: Obesity

Summary: the aim of the present research is to verify if the pleasantness of affective touch is comparable between women with obesity and healthy women, while measuring the level of social anhedonia and the lifespan experience of affective touch.


Eligibility criteria:
inclusion criteria: * right-handed; * diagnosis of obesity (i.e., the level of body mass index (bmi( greater than or equal to 30). exclusion criteria: * concurrent neurological, neurodevelopmental (e.g., autism), motor, somatosensory and/or psychiatric disorders * evidence of any skin-related condition possibly affecting sensitivity on the participants' forearm (e.g., eczema, scars).

Keywords: affective touch social anhedonia lifespan bodily contacts interpersonal relationships
effectiveness of the transcutaneous electrical nerve stimulation in dysmenorrhea

Conditions: Dysmenorrhea

Summary: hypothesis: what is the best modulation of pulse frequency in transcutaneous electrical nerve stimulation in dysmenorrhea? purpose: to determine the effect of hypoalgesia frequency modulation pulse by transcutaneous electrical nerve (tens) in dysmenorrhea. methods: a controlled clinical study and prospective developed at the school of physiotherapy clinic / ufpi. forty students were randomized into four distinct groups of the modulation frequency tens: group 1 - 100 hz, 100μs, group 2 - 4 hz, 100μs, group 3 - placebo (apparatus off), group 4 - placebo induced (2 hz, 40μs). all were initially evaluated by a questionnaire developed for the study, the visual analogue scale (vas) (before, after 20, 30, 40, 50, 60 minutes) and the mcgill pain questionnaire (before and after 20 minutes). the total duration of tens application was 20 minutes and all protocols were performed in a single session. the analysis of variance (one-way anova) followed by the tukey procedure was applied to identify differences between experimental groups for each variable analyzed. the level of significance was p\< 0,05.


Eligibility criteria:
inclusion criteria: * be the first or second day of menstruation * dysmenorrhea present at the time of application of tens * not having undergone any procedure analgesic six hours before the application of tens exclusion criteria: * not to mention dysmenorrhea at the time of evaluation * pregnant women * were using some method of hormonal contraception on an ongoing basis * had sensory deficits or cognitive and cases of contraindication to tens application.

Keywords: dysmenorrhea transcutaneous electrical nerve stimulation (tens analgesia pain visual analog scale mcgill pain questionnaire
observational study evaluating the use of intellivent® for patients with respiratory distress syndrome

Conditions: Respiratory Distress Syndrome

Summary: rational: intellivent is a ventilation mode completely automated which controls ventilation and oxygenation parameters. safety and performance of intellivent has still been demonstrated in post operative heart surgery for patient with a controlled ventilation on short period (2 to 4 hours). this feasibility study evaluate the use of intellivent for intensive care unit patients from intubation to coming off. primary objective : compare parameters which have been selected by automated mod (intellivent) to those selected by clinical practitioner in a conventional mode secondary objectives: record oxygenation , gaseous interchange and ventilation parameters. record complications, number of manual adjustments and prognostic signs. methodology: patients in the intensive care unit who need invasive ventilation. they will be included after a detailed information (information note). oxygenation and ventilation parameters will be recorded 2 times by day from intubation to coming off. the investigator in charge will determine daily at the bedside of the patient the adjustments he should make in a conventional mode. these adjustments will be compared to the intellivent automated adjustments. experimental study, observational, prospective, comparative, opened, monocentric in an intensive care unit. number of patients: 100


Eligibility criteria:
inclusion criteria: * patient which needs an invasive ventilation * intubation \< 24 hours * age ≥ 18 years exclusion criteria: * patient which has withdrawal standard in line with the unit coming off procedure (all criteria must be present) * temperature ≤ 38,5°c * no pressor drug * no sedation, * motor response to order, * cough during bronchoaspiration * %vm ≤ 130%, fio2 ≤ 50%, peep ≤ 5 cmh2o, pinsp ≤ 25 cmh2o. * patient with non invasive ventilation . * dysfunctions of the ventilatory command (ex cheyne-stokes). * broncho pleural fistula. * brain dead status. * pregnant woman. * adult under guardianship. * person deprived of liberty

Keywords: ventilation automated
anxiety disorders in children - association with neurodevelopmental delay/disorder

Conditions: Anxiety Disorders

Summary: the main objective of the study is to examine the relationship between anxiety disorders and neurodevelopmental disorder/delay in children aged 7- 13 years.

project summary anxiety disorders (ad's) in childhood are common and may cause great suffering.childhood ad's may persist into adulthood and knowledge of important risk factors for development and maintenance of these disorders is essential.the development of ad's is due to a complex interaction between biological and environmental factors.this study will examine the relationship between ad's and two biological risk factors:1.neurodevelopmental delays/disorders (ndd's) in motor and cognitive function and 2.temperament/personality.to date a few studies have consistently found that motor impairment is associated with childhood anxiety and predicts persistent anxiety in adolescence.the association between ad's and ndd's in cognitive functions such as language and attention is far less studied. in contrast, there is a huge research literature on temperament as a risk factor for ad's.the temperamental trait "behavioural inhibition" has been shown to be particularly associated with ad's.however, very few studies have examined the interplay between ndd's, temperament and anxiety.the study is a clinical case-control study of children aged 7-13 years with ad's referred to three different out-patient clinics.the participants will be assessed by diagnostic interviews, neuropsychological tests and temperament/personality instruments.comparison groups are:1.children with adhd (to compare ad's with another mental disorder related to ndd's) and 2.non-referred children without a mental disorder. follow-up at 6 months,1 and 5 years.a pilot study at two of the three out-patient clinics to be included,showed a sufficient sample size.anticipated implications of the study include increased knowledge of biological risk factors and of latent neurological brain correlates,as well as treatment implications.children with ndd's are often met with demands they cannot cope with due to their neurodevelopmental immaturity.to adjust the demands to the child's actual level of functioning is important.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of anxiety disorder or adhd or no diagnosis exclusion criteria: * clinical diagnosis of pdd * mental retardation * children whose both parents do not speak norwegian

Keywords: anxiety disorders children neurodevelopmental disorder neurodevelopmental delay temperament
to study the effects of host genetic factors on liver cirrhosis and hepatocellular carcinoma (hcc)

Conditions: Liver Cirrhosis

Summary: the purpose of this study is to identify genetic determinants of susceptibility to liver cirrhosis and hepatocellular carcinoma. it will assist in predicting individual risks of disease progression and would help to clarify pathophysiologic mechanisms of liver cirrhosis and hepatocellular carcinoma.

hepatocellular carcinoma (hcc) usually occurs in cirrhotic liver. only 10-30% of hcc occur in non-cirrhotic liver. it has been suggested that etiological factors may differ for hcc which develop in cirrhotic liver: hcc in non-cirrhotic liver might be less often associated with viral infection and chronic alcoholism than hcc in cirrhotic livers. however, in any individual, the factors that determine hcc with or without cirrhosis remain unknown. cirrhosis is the end of fibrosis progression. the progress of liver fibrosis is a complex progress involving many cytokines related to activation of the hepatic stellate cells and progressive accumulation of extracellular matrix. the key enzymes responsible for deposition and degradation of all the protein component of extracellular matrix and basement membrane are matrix metalloproteinases. to assess whether genetic variations in cytokines and matrix metalloproteinases result in diversity of liver cirrhosis and hcc, we conduct a case-control study of single nucleotide polymorphism analysis.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hepatocellular carcinoma * restrict the casual agent of liver disease to viral infection exclusion criteria: * the casual aget of liver disease is not viral infection, such as alcohol abuse

Keywords: single nucleotide polymorphism
prospective on market patient-reported outcomes for milli

Conditions: Vaginismus; Dyspareunia

Summary: to assess the effectiveness of the milli device in achieving vaginal intercourse

the milli vaginal dilator is a patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion. this study is intended to provide data in support of the milli vaginal dilator as a commercially available, over-the-counter medical device. the milli has been granted marketing authorization by the fda under premarket notification k220035 for the following indications for use statement: the milli vaginal dilator is a tool indicated for controlled dilation of the vagina. it can be used for dilation for an examination (by your doctor), in preparation for a surgical procedure, or to help relieve the symptoms of vaginismus (condition that involves tightening of the vaginal muscles) and related painful sex. .

Eligibility criteria:
inclusion criteria: * subject is a female at birth aged ≥18 years of age * subject is able to read and understand the approved, informed consent form (icf) * subject meets vaginismus and related painful sex/gpppd criteria as defined in the dsm-5, as confirmed by having one or more of the following for greater than 6 months: * pelvic pain * vaginal pain * pain with vaginal intercourse * pain with vaginal penetration * fear or anxiety about vaginal or pelvic pain with vaginal penetration * the inability to achieve vaginal penetration * subject currently has a sexual partner with a functional penis * subject is currently seeking vaginal penetration to achieve sexual intercourse * subject is currently unable to tolerate vaginal penetration to achieve sexual intercourse (score of ≤1 on peq question #1) * subject purchased milli vaginal dilator * subject is not contraindicated for milli vaginal dilator use * subject is able and willing to comply with study protocol exclusion criteria: * subject has previously participated in any studies by the company in the past 12 months or has used milli prior to enrollment * subject is pregnant * subject has an active pelvic infection (vagina or vulva) * subject has open wounds in the tissue inside or surrounding the vagina * subject has an untreated major mental health disorder (e.g., affective disorder, psychosis, ptsd) * subject has prior history of gender-confirming surgery, vaginal reconstruction surgery, pelvic radiation, and/or vaginal procedures that result in extensive scarring (with the exception of hysterectomy procedures) * subject or subject's partner experiences other conditions preventing intercourse (e.g., erectile dysfunction, lack of libido)

Keywords: painful sex dilation